Quantinno Capital Management LP Acquires 48,554 Shares of Fresenius Medical Care AG (NYSE:FMS)

Quantinno Capital Management LP grew its position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 78.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,078 shares of the company's stock after acquiring an additional 48,554 shares during the period. Quantinno Capital Management LP's holdings in Fresenius Medical Care were worth $2,345,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Wulff Hansen & CO. lifted its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock worth $6,556,000 after buying an additional 325,439 shares during the period. Moran Wealth Management LLC boosted its holdings in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock valued at $4,971,000 after acquiring an additional 74,621 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in Fresenius Medical Care by 60.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after purchasing an additional 23,692 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Fresenius Medical Care in the 3rd quarter worth $420,000. Finally, Triasima Portfolio Management inc. lifted its position in shares of Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company's stock worth $1,631,000 after purchasing an additional 18,360 shares during the period. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care Stock Performance

Shares of FMS stock traded down $0.08 during trading hours on Wednesday, reaching $23.82. 112,890 shares of the company traded hands, compared to its average volume of 355,724. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $24.31. The company has a market cap of $13.98 billion, a P/E ratio of 19.68, a P/E/G ratio of 0.98 and a beta of 0.93. The firm has a 50-day moving average price of $21.34 and a 200 day moving average price of $20.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Analysts Set New Price Targets

FMS has been the topic of a number of recent analyst reports. Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. StockNews.com started coverage on Fresenius Medical Care in a report on Thursday, November 28th. They set a "strong-buy" rating on the stock. Truist Financial lifted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Finally, Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $24.30.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.